[Cerebral toxoplasmosis developed after unrelated bone marrow transplantation for acute myeloid leukemia]

Rinsho Ketsueki. 2023;64(10):1275-1279. doi: 10.11406/rinketsu.64.1275.
[Article in Japanese]

Abstract

A 16-year-old boy received an unrelated bone marrow transplant while in second remission of acute myeloid leukemia. He suffered from severe oral mucosal complications and had difficulty taking oral drugs such as sulfamethoxazole/trimethoprim (ST). Engraftment was obtained on transplant day 35, and blurred vision and headache appeared around transplant day 60. Funduscopy revealed retinal hemorrhage and macular edema, and an MRI scan of the head revealed a nodular lesion in the left putamen. Toxoplasma gondii was detected by CSF PCR, and cerebral toxoplasmosis was diagnosed. Following therapy with ST and clindamycin, the patient was administered pyrimethamine, sulfadiazine, and leucovorin. Symptoms improved promptly, and CSF PCR was negative 45 days after the start of treatment. Since the prevalence of toxoplasma antibodies increases with age, it is crucial to avoid toxoplasma reactivation by ST after hematopoietic cell transplantation in postpubescent patients.

Keywords: Acute myeloid leukemia; Cerebral toxoplasmosis; Toxoplasma gondii; Unrelated bone marrow transplantation.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adolescent
  • Bone Marrow Transplantation / adverse effects
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Male
  • Toxoplasma*
  • Toxoplasmosis, Cerebral* / diagnosis
  • Toxoplasmosis, Cerebral* / drug therapy
  • Toxoplasmosis, Cerebral* / etiology
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

Substances

  • Trimethoprim, Sulfamethoxazole Drug Combination